Clinical management of metastatic colorectal cancer (MCRC) faces with different options and lines of treatment according to patients’ fitness [age, performance status (PS), comorbidities], extension of metastatic disease [liver-limited (L-L) or other/multiple metastatic (O/MM)], KRAS genotype (1–4). This evidence concerns the gene KRAS and metastatic colorectal cancer.